Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if KRRO is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
22 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 29 days ago
Red flags: 1
107 filers reported a long position in KRRO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Lynx1 Capital Management LP | $20.3M | 1.5M | Unchanged |
| NEA Management Company, LLC | $17.1M | 1.3M | Unchanged |
| Venrock Adviser, LLC | $13.3M | 1M | Unchanged |
| Atlas Venture Life Science Advisors, LLC | $12.7M | 962.9K | -15.3% |
| BALYASNY ASSET MANAGEMENT L.P. | $12.5M | 951.8K | -8.5% |
| BlackRock, Inc. | $10.8M | 817.6K | +77.7% |
| Affinity Asset Advisors, LLC | $9.3M | 706.9K | Unchanged |
| Nantahala Capital Management, LLC | $8.7M | 660K | Unchanged |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $7.1M | 541K | +136.9% |
| ADAR1 Capital Management, LLC | $7.1M | 540.1K | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.